- Home
- PBA vs UTHR Comparison
PBA vs UTHR Comparison
Compare PBA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- UTHR
- Stock Information
- Founded
- PBA 1997
- UTHR 1996
- Country
- PBA Canada
- UTHR United States
- Employees
- PBA N/A
- UTHR N/A
- Industry
- PBA Oil & Gas Production
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- PBA Energy
- UTHR Health Care
- Exchange
- PBA Nasdaq
- UTHR Nasdaq
- Market Cap
- PBA 22.6B
- UTHR 20.7B
- IPO Year
- PBA N/A
- UTHR 1999
- Fundamental
- Price
- PBA $37.06
- UTHR $446.81
- Analyst Decision
- PBA
- UTHR Buy
- Analyst Count
- PBA 0
- UTHR 12
- Target Price
- PBA N/A
- UTHR $495.08
- AVG Volume (30 Days)
- PBA 990.5K
- UTHR 591.7K
- Earning Date
- PBA 11-06-2025
- UTHR 10-29-2025
- Dividend Yield
- PBA 5.39%
- UTHR N/A
- EPS Growth
- PBA N/A
- UTHR 16.08
- EPS
- PBA 2.01
- UTHR 26.38
- Revenue
- PBA $5,750,633,574.00
- UTHR $3,128,400,000.00
- Revenue This Year
- PBA $11.24
- UTHR $13.68
- Revenue Next Year
- PBA $7.69
- UTHR $5.63
- P/E Ratio
- PBA $18.49
- UTHR $17.03
- Revenue Growth
- PBA 13.22
- UTHR 13.50
- 52 Week Low
- PBA $34.13
- UTHR $266.98
- 52 Week High
- PBA $43.44
- UTHR $479.50
- Technical
- Relative Strength Index (RSI)
- PBA 38.46
- UTHR 56.88
- Support Level
- PBA $37.17
- UTHR $430.02
- Resistance Level
- PBA $38.30
- UTHR $456.41
- Average True Range (ATR)
- PBA 0.56
- UTHR 14.19
- MACD
- PBA -0.04
- UTHR 0.19
- Stochastic Oscillator
- PBA 28.04
- UTHR 51.88
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.